SOLICITATION NOTICE
B -- Specialized Clinical Research Support for Studies of Patients with Xeroderma Pigmentosum, Trichothiodystrophy and Related Disorders
- Notice Date
- 8/7/2009
- Notice Type
- Presolicitation
- NAICS
- 621111
— Offices of Physicians (except Mental Health Specialists)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90174-KM
- Archive Date
- 9/8/2009
- Point of Contact
- Caren N Rasmussen, Phone: (301) 402-4509, Karri L. Mares, Phone: 3014357774
- E-Mail Address
-
cr214i@nih.gov, maresk@mail.nih.gov
(cr214i@nih.gov, maresk@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis Specialized Clinical Research Support for Studies of Patients with Xeroderma Pigmentosum, Trichothiodystrophy and Related Disorders from the University Dermatology, Inc.; 593 Eddy St. APC-10; Providence, RI 02903. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 621111 the business size standard is $10 million. Period of Performance shall be for seven (7) months from date of award. The DNA Repair Group of the Basic Research Laboratory (BRL) at NCI is studying molecular, cellular and clinical abnormalities in human cancer-prone genetic diseases using the study approach involving parallel molecular and clinical investigations of DNA repair defects in patients with genetic diseases and in the general population. Xeroderma pigmentosum (XP) is a rare inherited disorder due to a variety of underlying defects in the repair of DNA. Patients with XP develop very large numbers of skin cancers. Skin cancer is not only common in XP patients but - is the most common cancer that occurs in the general population. The DNA Repair Group is actively working to identify and study families with XP from clinical and a molecular perspective in order to better identify and delineate the features of this disease. This work is important not only to understand the pathogenesis of this condition, and also to better understand how variations in DNA repair relate to skin cancer in the general population. The purpose of this project is to correlate clinical phenotype with the specific underlying genetic abnormality to make genotype/ phenotype correlations. Contractor shall be responsible for evaluation, diagnosis and management of patients - with rare skin disorders including XP and related conditions such as trichothiodystrophy (TTD) and shall be licensed, board certified dermatologists. Work will be performed at NIH/NCI. University Dermatology, Inc. has unique expertise in the clinical evaluation of patients with hereditary skin disorders and their treatment, especially those with cancer predisposition such as xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Their expertise is needed in the evaluation, diagnosis, and management of these disorders. In order to successfully complete the accrual and assessment of patients it is necessary to have clinical dermatology expertise in the area of the evaluation, diagnosis and management of patients with rare skin disorders, particularly xeroderma pigmentesum (XP), trichothiodystrophy (TTD) and related conditions. University Dermatology, Inc. has licensed, board certified dermatologists with specific expertise in the clinical evaluation of patients with XP, TTD, and related disorders. This expertise is not duplicated elsewhere, and there is no substitute. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on August 7, 2009. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Karri Mares, Contract Specialist at maresk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation No. NCI-90174-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90174-KM/listing.html)
- Record
- SN01903726-W 20090809/090808000651-f4a68c41a3d3ff76714074a26b81e839 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |